Beam Therapeutics' Role In Gene-Editing 2.0 Revolution: First U.S. Patient Treated With Base-Edited Cell Therapy
Portfolio Pulse from Vandana Singh
Beam Therapeutics Inc has announced that the first patient was treated with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therapy, marking a significant milestone for the company and the gene editing sector. Analysts from William Blair maintain an Outperform rating for Beam Therapeutics, considering the company to be at the forefront of the next wave of gene-editing companies. Beam's shares are down 0.38% at $23.37 on the last check Tuesday.
September 05, 2023 | 5:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Beam Therapeutics treated the first patient with its gene-editing therapy, BEAM-201. Analysts maintain an Outperform rating for the company, which is seen as a leader in the gene-editing sector.
The news of the first patient being treated with Beam's gene-editing therapy is a significant milestone for the company and could potentially boost investor confidence in the company's technology and future prospects. The maintained Outperform rating by analysts further supports this positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100